Wellcome Leap's R3 program, jointly funded by the Coalition for Epidemic Preparedness Innovations, seeks to increase the development and deployment of RNA-based biologic products as a standardized platform technology with reduced costs. In addition, the program aims to create a global network of state-of-the-art manufacturing facilities.

RNA development relies on the ability to rapidly design and produce genetic material. DNA Script's Syntax platform employs enzymatic DNA synthesis. R3's digital-sequence-to-RNA unique production technologies will help realize the ability to produce genetic material with exceptionally low error rates for plasmid DNA, according to the company.

DNA Script is a life sciences technology company developing a new, faster, more powerful and versatile way to design and manufacture nucleic acids.

DNA Script raises $200M in series C financing round
DNA Script has completed a series C financing round, raising $200 million. The company has raised a total of $315 million since it was founded...

DNA Script adds $165M to coffers
DNA Script has raised $165 million in a series C financing round led by Coatue Management and Catalio Capital Management.

DNA Script joins Genome Project-write's advisory board
DNA Script has joined the industrial advisory board of Genome Project-write, which has developed a computer-aided design tool for genome design.

DNA Script launches benchtop DNA printer
DNA Script has launched Syntax, a benchtop DNA printer designed for molecular biology and genomics applications. The printer is designed to enable onsite...